Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Oct;18(10):854-63.
doi: 10.1046/j.1525-1497.2003.20910.x.

Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model

Affiliations
Review

Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model

Catherine Kim et al. J Gen Intern Med. 2003 Oct.

Abstract

Screening and treatment rates for dyslipidemia in populations at high risk for cardiovascular disease (CVD) are inappropriately low and rates among women may be lower than among men. We conducted a review of the literature for possible explanations of these observed gender differences and categorized the evidence in terms of a conceptual model that we describe. Factors related to physicians' attitudes and knowledge, the patient's priorities and characteristics, and the health care systems in which they interact are all likely to play important roles in determining screening rates, but are not well understood. Research and interventions that simultaneously consider the influence of patient, clinician, and health system factors, and particularly research that focuses on modifiable mechanisms, will help us understand the causes of the observed gender differences and lead to improvements in cholesterol screening and management in high-risk women. For example, patient and physician preferences for lipid and other CVD risk factor management have not been well studied, particularly in relation to other gender-specific screening issues, costs of therapy, and by degree of CVD risk; better understanding of how available health plan benefits interact with these preferences could lead to structural changes in benefits that might improve screening and treatment.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Conceptual model of patient, clinician, and health system factors affecting management of cholesterol in high-risk patients.

Similar articles

Cited by

References

    1. American Heart Association. American Heart Association 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001. pp. 1–38.
    1. Miettinen T, Pyorala K, Olsson A, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation. 1997;96:4211–8. - PubMed
    1. McPherson R, Genest J, Angus C, Murray P. The Women's Atorvastatin Trial on Cholesterol (WATCH): frequency of achieving NCEP-II target LDL-C levels in women with and without established CVD. Am Heart J. 2001;141:949–56. - PubMed
    1. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57. - PubMed
    1. Lewis S, Sacks F, Mitchell J, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction. The Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol. 1998;32:140–6. - PubMed

Publication types